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Pulmonary Alveolar Proteinosis (PAP) is a rare syndrome characterized by pulmonary surfactant accumulation within
the alveolar spaces. It occurs with a reported prevalence of 0.1 per 100,000 individuals and in distinct clinical forms:
autoimmune (previously referred to as the idiopathic form, represents the vast majority of PAP cases, and is
associated with Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) auto-antibodies; GMAbs), secondary
(is a consequence of underlying disorders), congenital (caused by mutations in the genes encoding for the GM-CSF
receptor), and PAP-like syndromes (disorders associated with surfactant gene mutations). The clinical course of PAP
is variable, ranging from spontaneous remission to respiratory failure. Whole lung lavage (WLL) is the current
standard treatment for PAP patients and although it is effective in the majority of cases, disease persistence is not
an unusual outcome, even if disease is well controlled by WLL.
In this paper we review the therapeutic strategies which have been proposed for the treatment of PAP patients and
the progress which has been made in the understanding of the disease pathogenesis.
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Pulmonary alveolar proteinosis (PAP) is a diffuse pul-
monary disease characterized by the accumulation of
periodic acid-Schiff (PAS)-positive lipoproteinaceous
material, primarily phospholipid surfactant and surfac-
tant apoproteins, in the distal air spaces, which results
in impaired gas transfer.
PAP is an extremely rare disorder, occurring worldwide
with an estimated prevalence of 0.1 per 100,000 indivi-
duals. The clinical course of PAP is variable, ranging from
spontaneous remission to respiratory failure. The onset of
clinical disease is insidious, with a subacute indolent
course that often delays the diagnosis by months to years.
This delay is secondary to the time required for suffi-
cient surfactant accumulation in the alveoli to impair
gas exchange. In fact, decreased clearance of surfactant
from the alveoli has been postulated as the basis of PAP
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Major advancements have been achieved in the under-
standing of the pathogenesis in the last two decades.
The first milestone was the discovery in GM-CSF
knockout mice that surfactant lipids and proteins progres-
sively accumulate in the alveolar space, as in human PAP
[1,2]. These findings revealed an unexpected critical role
of GM-CSF in the homeostasis of surfactant in humans.
However, unbound immunoreactive GM-CSF is detectable
in BAL fluid and plasma of PAP patients [3], thus
researchers postulated that an inhibitory circulating factor
could play a role in the pathogenesis of the disorder. With
this hypothesis they laid the groundwork for the discovery
of the neutralizing autoantibodies directed against GM-CSF
(Abs) [4] which were proposed as the causative agent for
autoimmune PAP, by impairing the function of alveolar
macrophages in surfactant clearance. Later, Uchida and
coworkers [5] demonstrated that in patients with PAP, the
presence of GM-CSF autoantibodies was associated with
impaired microbicidal activity by neutrophils, thus explain-
ing the basis for the supposed systemic impairment of de-
fence mechanisms in PAP. When highly purified GM-CSF
autoantibodies, deriving from a patient with autoimmuneLtd. This is an Open Access article distributed under the terms of the Creative
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pathologic manifestations of the human disorder were
reproduced, thus demonstrating the causative nature of
these autoantibodies [6].
PAP classification
The vast majority of PAP (more than 90% of all reported
cases) are classified as the autoimmune disease type,
associated with the presence of GM-CSF autoantibodies.
Less commonly is the congenital type (caused by muta-
tions in genes coding for surfactant protein – B or –C,
ABCA3, and α chain of the granulocyte-macrophage
colony-stimulating factor receptor, GM-CSF-Rα) or the
secondary type (forms associated with hematologic or
solid malignancies, inhalation of inorganic agents,
chemotherapy treatment, opportunistic infections and
lysinuric protein intolerance).
When reviewing the therapeutic strategies for PAP, it is
important to note that the various forms of PAP may re-
quire different treatments, even though whole lung lavage
(WLL) is the current therapeutic standard.
Autoimmune PAP has been treated successfully since
the early 1960s by WLL, with significant improvements
in symptoms and radiographic results. In the pre-whole
lung lavage era, death occurred mostly because of pro-
gressive respiratory failure and, to a lesser extent, super-
imposed respiratory opportunistic infections. The high
frequency of respiratory infections, including those from
opportunistic agents, supports the hypothesis of an im-
pairment in lung immunity. However the presence of
infections occurring also outside the lung, would suggest
a systemic impairment of host defences.
Current therapy for the congenital form of the disorder
depends on the patient’s age at presentation, severity of
symptoms and anticipated disease course. In these cases
the therapeutic approach is supportive, although successful
lung transplantation has been reported.
Therapy for secondary PAP generally involves treatment
of the underlying condition. For example, when the dis-
order is associated with a hematologic cancer, successful
chemotherapy or bone marrow transplantation corrects
the associated pulmonary disorder.
WLL
The first advance in the treatment of PAP came in 1960,
when Dr. José Ramirez-Rivera applied repeated “segmental
flooding” as a means of physically removing the accumu-
lated alveolar material. This “segmental flooding” provided
proof that physical removal of adequate amounts of the
material provided functional improvement, but as initially
described, this was clearly an impractical therapy for broad
application. Over the next fifty years, this procedure was
sequentially refined through the routine use of general
anesthesia [7,8], increased lavage volumes [9], the use ofsaline alone [10-12], the addition of concomitant chest
percussion [13] and the successful completion of bilateral
sequential WLL in the same treatment session [14]. In
addition, depending on the severity of hypoxia, this pro-
cedure may be performed with the assistance of partial
extracorporeal membrane oxygenation [15].
The principal criticism of this procedure is that WLL
has not been standardized and no perspective clinical
trials have been performed. As a result, WLL has been
modified by each center [16] and a number of publica-
tions deal step by step with the technical issues [17-19].
Even if randomized clinical trials are lacking, available
evidence suggests that WLL is far more effective than
any other intervention.
The WLL technique at the Pavia Center is performed
under general anaesthesia in an operating room or an in-
tensive care unit. The patient is intubated with a double-
lumen endotracheal tube and fibre-optic bronchoscopy is
performed to confirm the appropriate tube placement.
The patient is placed in the lateral decubitus position; the
lung is lavaged in the uppermost position, while the non-
lavaged lung is mechanically ventilated. 500–600 mL of
warmed (37°C) saline is injected in the lung. Fluid is then
collected by gravity after opening the outflow tube. Man-
ual chest percussion may be performed to improve drain-
age. When the outflow, initially milky, becomes clear,
chest wall percussion, which restarts and greatly enhances
the removal of proteinaceous material, is added. Lavage
and percussion are continued until the outflow fluid be-
came definitively clear, which may take 3 hrs and a total of
15–20 L saline for a single lung [20].
Although there are no clearly established criteria for
when to perform WLL, the recommendations indicated
in available reports include: presence of persistent or
progressive respiratory failure; absence of respiratory dif-
ficulty at rest, but presence of exercise desaturation
(>5% points); in selected cases, WLL may be discussed if
a PAP patient, in particular a young adult, reports a sig-
nificant limitation in daily or sport activities [21].
WLL is generally well tolerated. The major adverse effect
of WLL is hypoxemia, especially during the emptying
phase, which decreases airway pressure and increases the
perfusion of the lavaged lung. Among potential complica-
tions, intraoperative resistance tends to be more common
when the first lung is being lavaged. Other more common
and less dangerous complications include pneumothorax,
pleural effusion, and hydropneumothorax, which can be
avoided by meticulous charting of the infused saline solu-
tion versus the output, and by taking care not to allow in-
stilled fluid to exceed the fluid drained by more than a few
hundred milliliters in consecutive lavages [19].
There are few contraindications, the most common is
uncorrectable low oxygen saturation, convulsions and
fever, which may indicate infection. Cardiopulmonary
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lead to a fairly rapid improvement in oxygenation once
the proteinaceous material is washed out of the alveoli
[19]. However, over time the WLL technique has been
continuously improved, thus careful assessment during
the preparation and WLL, as well as the choice of the
nondependent lung lavage procedure, will allow even se-
verely impaired PAP patients to be treated successfully.
WLL improves survival, with the proportion of subjects
free from recurrent PAP reaching >70% at 7 yrs [20]. In a
long-term follow up of the Pavia series of 81 PAP patients
(collected from 1989 to 2011) we found that the procedure
was potentially safe and efficacious with long lasting bene-
fits. Patients showed symptomatic, radiographic and func-
tional improvement after whole lung lavage. Of the 47
patients lavaged, 32 underwent a single WLL, and 15
patients underwent more than one WLL. The remaining
34 PAP patients were not submitted to WLL, for different
reasons (spontaneous resolution or improvement, minimal
functional impairment not requiring treatment, consent
refusal).
Bronchofiberscopiclobar lavage
When WLL with generalized anesthesia may be hazardous
and in paediatric patients, where the use of WLL is less
well established mainly because of the technical difficulties
associated with the use of large endotracheal tube, the
treatment with multiple segmental or lobar lavage by
fiberoptic bronchoscopy is considered safer [22-24]. The
main advantage is the possibility to perform it under
local anesthesia. The procedure is performed by
repeated instillation of 50 mL aliquots of normal saline
into a lobe until the returning fluid becomes clear. Lavage
is performed in one lobe at up to six different sessions
with a gap of two to three days, and the amount of lavage
fluid is about 10 times less than that required for WLL.
Exogenous granulocyte macrophage colony stimulating
factor (GM-CSF) therapy
Subcutaneous GM-CSF
Although WLL is still considered the gold standard for
treatment, the discovery of alveolar macrophage involve-
ment and anti GM-CSF neutralizing antibodies led to
the use of GM-CSF as a potential therapeutic approach
for PAP. Since it is conceivable that the alveolar space is
the site of GM-CSF signal disruption, with the impair-
ment of surfactant catabolism in autoimmune PAP, then
it is reasonable to propose that local GM-CSF supple-
mentation would result in better treatment outcome.
Evaluation of GM-CSF augmentation as a potential ther-
apy in autoimmune PAP was initially prompted by the
demonstration of restorative activities of this cytokine
on impaired surfactant metabolism and innate immunity
in GM-CSF deficient mice [25]. So far, only a limitednumber of PAP patients have been treated with GM-
CSF by subcutaneous administration. The first patient
with idiopathic PAP in whom recombinant human GM-
CSF subcutaneous therapy was applied, was reported in
1996 [26]. GM-CSF treatment resulted in a transient im-
provement in exercise capacity, and the alveolar-arterial
oxygen gradient (A-aDO2).
Later, Seymour and colleagues treated 14 patients over a
three month period. Patients not responding to the initial
dose of 5 μg/kg/d GM-CSF underwent stepwise dose es-
calation until a therapeutic response (represented by im-
provement in oxygenation at the lung level) was obtained.
The overall response rate was 43% and lasted a me-
dian duration of 39 weeks. Exogenous GM-CSF was well
tolerated, and no late side effects were reported [27].
Subsequently, in an open-label study on 25
patients, using escalating doses of GM-CSF from 5 to
18 Mg/kg/day, GM-CSF treatment was associated with
amelioration of clinical and quality-of-life-related para-
meters only in 48%, with relapse rates of 25% among
responders [28]. However this PAP series, which is the
largest to date for subcutaneous therapy, considered
only subjects with moderate symptomatic disease, there-
fore we cannot speculate on the role of this treatment in
severe forms of PAP.
The results on the role of GM-CSF antibody titer as a
predictor of response to GM-CSF therapy are conflicting.
Two papers by Bonfield and coworkers [29,30] suggest
that PAP patients with low GMAbs titer have less active
disease and respond to subcutaneous GM-CSF with a
further decline in autoantibodies. On the contrary, Sey-
mour and colleagues [31] did not find correlation be-
tween serum autoantibodies and PAP severity. They
suggest that delayed diagnosis, normal serum LDH levels,
higher vital capacity and plasma levels of SP-B (Surfactant
Protein-B) before treatment, and peak eosinophil counts
following GM-CSF are markers of response to GM-CSF
therapy. However, none of these are conclusive and are not
accepted as prognostic variables.
Inhaled GM-CSF
In a retrospective series, patients with idiopathic PAP
were treated with aerosolized GM-CSF [32]. In this
study, 12 PAP patients were treated with 250 mg
aerosolized GM-CSF twice daily on alternate weeks for
24 weeks. All patients except one had a positive response.
Two patients made a complete recovery and were dis-
ease free one and two years after discontinuing treat-
ment. Four patients showed complete response to both
the initial course or when treated again for recurrence
after discontinuation of treatment. One patient required
dose escalation and had a complete response. GM-CSF
was well tolerated without late toxicity after a median
(range) followup of 30.5 (3–68) months.
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inhaled GM-CSF in 39 patients with autoimmune PAP.
The study group received high-dose GM-CSF (125 μg
twice daily on days 1–8 for six 2-week cycles) followed
by low-dose (125 μg once daily on days 1–4 for six 2-week
cycles) over a six month study period. The authors showed
a response rate of 62% that was maintained in 83%
patients at a one year follow up [33]. Overall these findings
provide evidence that aerosolized GM-CSF is safe and ef-
fective in treating pulmonary alveolar proteinosis.
It has also been demonstrated that GM-CSF inhalation
therapy decreases markers of surfactant accumulation,
including total protein and SP-A (Surfactant Preotein-A)
in the BAL fluid of high responders [34]. In particular,
among 94 biomarkers screened, they found that the con-
centration of interleukin-17 and cancer antigen-125 were
significantly increased after GM-CSF inhalation treatment.
Very recently, the results of a meta-analysis of observa-
tional studies [35] suggest a cumulative response rate of
59% with GM-CSF therapy in autoimmune PAP, with a
trend towards better response via the inhaled route com-
pared to the subcutaneous route. Moreover, almost 30%
of the GM-CSF responders relapsed during followup; the
number of relapses was less in the inhaled versus the
subcutaneous group, because of the local deposition at
the alveolar space which is the putative site of GM-CSF
signal disruption.
The authors of this meta-analysis speculate on the the-
oretical possibility of inadequate deposition of GM-CSF
with the inhaled route, due to the presence of surfactant
in the alveolar spaces, which would not be a problem
with the subcutaneous route. However, we have to keep in
mind that administration of GM-CSF via the inhalation
route shows the best efficacy and prevents hematopoietic
toxicity, especially on the long-term basis, encountered
with subcutaneous administration [36].
There is usually a lag period of 6–12 weeks in the sub-
cutaneous treatment group and 4–12 weeks in the
inhaled group prior to clinical response. This is probably
due to the time required for GM-CSF to mobilize
hematopoietic progenitor cells into peripheral blood and
stimulate them to differentiate into functional alveolar
macrophages in the lung.
The overall response rate of GM-CSF therapy is lower
compared with WLL, in fact it seems only to limit disease
progression. For this reason, it has been proposed as stand-
alone therapy in PAP patients with less severe disease and
as a supplementary therapy to WLL in patients with more
advanced autoimmune PAP [36].
In this context, a decrease in GM-CSF requirements
was shown by performing WLL, followed by nebulized
GM-CSF [37]. It also appears that high amounts of
exogenous GM-CSF can overcome the endogenous
neutralizing antibodies; especially if GM-CSF is directlyadministered to the lung. This seems to be due to the
lipoproteinaceous material acting as a barrier, which
once cleared by WLL allows inhaled GM-CSF to more
readily reach the alveoli.
At the Pavia center, a study protocol has been re-
cently started with WLL followed by inhaled GM-CSF
(Sargramostin) in the treatment of Autoimmune PAP
(AIFA FARM7MCPK4).Plasmapheresis
The presence of systemic anti GM-CSF antibodies in
idiopathic PAP led to the hypothesis that PAP could be
an autoimmune disease and hence the rationale for
plasmapheresis as a therapeutic option. A 41-year old
nonsmoker woman with a 5-year history of non-resolving
pulmonary infiltrates was the first case of PAP treated with
plasmapheresis. She was refractory to repeated WLL ses-
sions and subcutaneous GM-CSF. On a compassionate
basis, she was treated with plasmapheresis, 1.5 plasma
volume exchanges on ten separate sessions over a 2-month
period. One of these episodes was complicated by gram-
negative sepsis and respiratory failure. She subsequently
recovered from this, and her anti–GM-CSF antibody titer
was reduced, with improvement in symptoms, oxygen-
ation, and radiographs [38]. No long-term followup data
on this patient are available.
Subsequently, a patient with autoimmune PAP, pre-
senting with persistent disease despite three WLL treat-
ments over 10 months, was treated with plasmapheresis
with ten 1.5-L plasma exchanges. Plasmapheresis low-
ered the serum autoantibody level, but did not improve
respiratory impairment. Further WLL therapy was
required, but it was transiently effective, with increased
length of symptom-free periods between subsequent
WLLs [39].Biological therapy
Reducing the autoantibody level by depleting B cells is a
novel approach for PAP. Rituximab is a monoclonal anti-
body directed against the CD20 antigen of B-lymphocytes.
It has been demonstrated to be effective in various diseases
mediated by autoantibodies, such as rheumatoid arthritis,
idiopathic thrombocytopaenicpurpura and systemic lupus
erythematosus. Rituximab was observed to be useful in the
treatment of patients with unresponsive PAP. Two single-
cases have been described: Borie et al. [40] described a
41-yr-old nonsmoker who refused whole lung lavage and
exhibited clinical, functional and radiographic improve-
ment six months after rituximab therapy (1 g iv on days 1
and 15), while Amital et al. [41] described a 40-yr-old non
smoker with severe dyspnoea and hypohaemia. WLL and
GM-CSF initially resulted in partial remission, but a year
later the patient’s condition deteriorated and only after
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rest and during exercise dramatically improved.
The first prospective, open-label, proof-of-concept
rituximab trial was conducted in 10 PAP patients [42].
Intervention consisted of two intravenous infusions of
rituximab (1000 mg), fifteen days apart. Post-therapy fol-
lowup was obtained in seven out of 10 patients. The
most striking clinical finding was improvement in oxy-
genation. Improvements were also noted in TLC, HRCT
scans and a transitional dyspnoea index. Importantly,
neither the total serum anti-GM-CSF nor the serum
GM-CSF neutralizing capacity were reduced following
rituximab therapy. On the contrary, reduction in anti-
GM-CSF levels in BAL fluid from the lung correlated with
disease changes, suggesting that disease pathogenesis is
related to autoantibody levels in the target organ. The
data from this study also indicated that rituximab was
well tolerated, with no major adverse reactions in this
PAP cohort.
Conclusions
Over the last two decades we have greatly increased our
understanding of the pathogenesis of PAP. Studies in
mice, in primates and lastly in humans, represent the
successful pathway of translational research, by which
the results obtained in animal models were quickly
transferred to patients. The discovery of the critical role
played by neutralizing autoantibody against GM-CSF,
which causes a defect in the function of alveolar macro-
phages linked to the disruption of surfactant homeostasis,
has led to the development of a diagnostic test with a very
high sensitivity and specificity. Following this research line
we will soon be able to attain a better comprehension of
the biological and immunological mechanisms regulating
not only PAP etiology, but also lung homeostasis.
In this context, even if a new alternative therapy to
WLL has not yet emerged, modulation of the GM-CSF
signaling pathway or novel biological approaches seem
to be promising.
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